<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC7350214\results\search\disease\results.xml">
  <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Emerging" exact="influenza" post="viruses pose an extreme global risk to human health,"/>
  <result pre="health, resulting in an urgent need for effective vaccination against" exact="influenza" post="infection. Adjuvants are vital components that can improve vaccine"/>
  <result pre="named EcML, in enhancing the immunogenicity and efficacy of an" exact="influenza" post="vaccine. Similar to MPL, EcML activated dendritic cells and"/>
  <result pre="that EcML might be a promising vaccine adjuvant for preventing" exact="influenza" post="virus infection. adjuvant vaccine efficacy influenza virus monophosphoryl lipid"/>
  <result pre="vaccine adjuvant for preventing influenza virus infection. adjuvant vaccine efficacy" exact="influenza" post="virus monophosphoryl lipid A antibody production cytotoxic T lymphocyte"/>
  <result pre="lipid A antibody production cytotoxic T lymphocyte 1. Introduction The" exact="influenza" post="virus poses a serious global threat to human health"/>
  <result pre="can cause pandemics associated with high mortality worldwide [1]. While" exact="influenza" post="vaccines have been used in many countries, the seasonal"/>
  <result pre="influenza vaccines have been used in many countries, the seasonal" exact="influenza" post="epidemics have not been well controlled. In addition, the"/>
  <result pre="well controlled. In addition, the outbreak of the swine-origin H1N1" exact="influenza" post="in 2009 resulted in an estimated 300,000 deaths [2,3],"/>
  <result pre="in an estimated 300,000 deaths [2,3], explicitly demonstrating how the" exact="influenza" post="vaccination was insufficient for controlling a potential pandemic. Consequently,"/>
  <result pre="control influenza. One approach to improve the effectiveness of the" exact="influenza" post="vaccine is to include adjuvants. While adjuvants have been"/>
  <result pre="alum, MF59, and AS03, which are included in currently licensed" exact="influenza" post="vaccines [4]. Despite the fact that alum induces humoral"/>
  <result pre="including pain at injection sites and the induction of inflammatory" exact="arthritis" post="[6]. Moreover, cases of rare sleeping disorders and narcolepsy"/>
  <result pre="inflammatory arthritis [6]. Moreover, cases of rare sleeping disorders and" exact="narcolepsy" post="after vaccination with AS03-adjuvanted vaccines were reported [7,8]. Therefore,"/>
  <result pre="used in licensed vaccines for human papillomavirus [15] and the" exact="hepatitis" post="B virus [16]. Thus, developing TLR4 ligands as adjuvants"/>
  <result pre="adjuvants could be beneficial to improving antiviral vaccines such as" exact="influenza" post="vaccine. Monophosphoryl lipid A (MPL) is a detoxified derivative"/>
  <result pre="adjuvanticity of EcML in enhancing the pandemic H1N1 (pH1N1, A/California/04/09)" exact="influenza" post="vaccine efficacy. EcML improved the protective efficacy of the"/>
  <result pre="suggest that EcML might be a promising adjuvant candidate for" exact="influenza" post="vaccines. 2. Materials and Methods 2.1. Mice and Cells"/>
  <result pre="obtained from InvivoGen. 2.3. Preparation of Influenza Virus The pH1N1" exact="influenza" post="virus was grown in 9- to 10-day-old SPF embryonated"/>
  <result pre="collected on day 14 after the last immunization. In the" exact="influenza" post="experiment, the mice were i.m. immunized with pH1N1 split"/>
  <result pre="challenged with a lethal dose (50 LD50) of the pH1N1" exact="influenza" post="virus. The body weight and survival of the challenged"/>
  <result pre="were sacrificed. 2.8. HI Assay HI titers against the pH1N1" exact="influenza" post="virus were determined using sera from the vaccinated mice,"/>
  <result pre="500 median tissue culture infectious dose (TCID50)/well of UV-inactivated pH1N1" exact="influenza" post="virus for 3 days at 37 Â°C. The spot-forming"/>
  <result pre="of Influenza Vaccine Antigen To evaluate whether EcML improves the" exact="influenza" post="vaccine efficacy, we examined the effects of EcML on"/>
  <result pre="challenged with a lethal dose (50 LD50) of the pH1N1" exact="influenza" post="virus. As shown in Figure 6A, mice vaccinated with"/>
  <result pre="adjuvant effects of EcML on the protection against the pH1N1" exact="influenza" post="virus challenge, we examined the influenza-specific humoral and cellular"/>
  <result pre="splenocytes of the vaccinated mice. Our results showed that the" exact="influenza" post="vaccine antigen-specific IgG, IgG1, and IgG2b titers were higher"/>
  <result pre="Moreover, the ELISPOT assay showed that the number of pH1N1" exact="influenza" post="virus-specific IFN-Î³ secreting cells was significantly higher in the"/>
  <result pre="suggest that EcML improves the protective efficacy of the pH1N1" exact="influenza" post="vaccine antigen by enhancing influenza-specific humoral and cellular immune"/>
  <result pre="immune responses. 4. Discussion Despite the availability of annual vaccinations," exact="influenza" post="remains a significant cause of human infectious disease and,"/>
  <result pre="of annual vaccinations, influenza remains a significant cause of human" exact="infectious disease" post="and, thus, there is a push to improve vaccine"/>
  <result pre="vaccine immunogenicity without compromising safety would be beneficial to improving" exact="influenza" post="vaccines. However, the main influenza vaccine adjuvants, including alum,"/>
  <result pre="would be beneficial to improving influenza vaccines. However, the main" exact="influenza" post="vaccine adjuvants, including alum, MF59, and AS03, have limitations"/>
  <result pre="adjuvant in several human vaccines [19] and has reported increasing" exact="influenza" post="vaccine efficacy [28]. However, its disadvantages, including the difficult"/>
  <result pre="Ultimately, EcML effectively improved the protective immunity of the pH1N1" exact="influenza" post="vaccine antigen. DCs play a major role in innate"/>
  <result pre="Previous studies have reported that children vaccinated with the MF59-adjuvanted" exact="influenza" post="vaccine showed adverse reactions, including redness and swelling at"/>
  <result pre="to MPL. Currently, alum and MF59 are mainly used in" exact="influenza" post="vaccines [4], but these adjuvants primarily induce responses toward"/>
  <result pre="and may not be sufficiently effective in the protection against" exact="influenza" post="virus infections. We then evaluated the efficacy of EcML"/>
  <result pre="evaluated the efficacy of EcML as an adjuvant for the" exact="influenza" post="vaccine, in comparison to alum. We found that EcML"/>
  <result pre="alum only partially protected mice (20% survival rate) against pH1N1" exact="influenza" post="virus infection. MPL has been reported to enhance the"/>
  <result pre="has been reported to enhance the protective efficacy of the" exact="influenza" post="vaccine [28]. We observed that EcML provided similarly protective"/>
  <result pre="the pH1N1 vaccine is beneficial for the protection against different" exact="influenza" post="virus subtypes. We observed that the EcML-vaccine group had"/>
  <result pre="has been used in licensed vaccines for human papillomavirus and" exact="hepatitis" post="B virus [43,44]. Thus, the combination of EcML with"/>
  <result pre="drastically increased the protective efficacy of the pH1N1 vaccine against" exact="influenza" post="virus infection by enhancing Ab production, HI titers, CTL"/>
  <result pre="promising adjuvant that may be capable of providing protection from" exact="influenza" post="virus infections. Supplementary Materials The following are available online"/>
  <result pre="conflict of interest. References References 1.Bar-OnY.GlasnerA.MeningherT.AchdoutH.GurC.LankryD.VitenshteinA.MeyersA.F.MandelboimM.MandelboimO.Neuraminidase-mediated, nkp46-dependent immune-evasion mechanism of" exact="influenza" post="virusesCell Rep.201331044105010.1016/j.celrep.2013.03.03423602571 2.GlezenW.P.Emerging infections: Pandemic influenzaEpidemiol. Rev.199618647610.1093/oxfordjournals.epirev.a0179178877331 3.DawoodF.S.IulianoA.D.ReedC.MeltzerM.I.ShayD.K.ChengP.Y.BandaranayakeD.BreimanR.F.BrooksW.A.BuchyP.et al.Estimated"/>
  <result pre="mortality associated with the first 12 months of 2009 pandemic" exact="influenza" post="a h1n1 virus circulation: A modelling studyLancet Infect. Dis.20121268769510.1016/S1473-3099(12)70121-422738893"/>
  <result pre="a h1n1 virus circulation: A modelling studyLancet Infect. Dis.20121268769510.1016/S1473-3099(12)70121-422738893 4.TregoningJ.S.RussellR.F.KinnearE.Adjuvanted" exact="influenza" post="vaccinesHum. Vaccines Immunother.20181455056410.1080/21645515.2017.1415684 5.MarrackP.McKeeA.S.MunksM.W.Towards an understanding of the adjuvant"/>
  <result pre="and prospects on controlled release adjuvancitySaudi. Pharm. J.20111919720610.1016/j.jsps.2011.06.00323960760 7.MillerE.AndrewsN.StellitanoL.StoweJ.WinstoneA.M.ShneersonJ.VerityC.Risk of" exact="narcolepsy" post="in children and young people receiving as03 adjuvanted pandemic"/>
  <result pre="children and young people receiving as03 adjuvanted pandemic a/h1n1 2009" exact="influenza" post="vaccine: Retrospective analysisBMJ2013346f79410.1136/bmj.f79423444425 8.NohynekH.JokinenJ.PartinenM.VaaralaO.KirjavainenT.SundmanJ.HimanenS.L.HublinC.JulkunenI.OlsenP.et al.As03 adjuvanted ah1n1 vaccine associated"/>
  <result pre="associated with an abrupt increase in the incidence of childhood" exact="narcolepsy" post="in finlandPLoS ONE20127e3353610.1371/journal.pone.003353622470453 9.KumarH.KawaiT.AkiraS.Toll-like receptors and innate immunityBiochem. Biophys."/>
  <result pre="greatly enhances the efficacy and heterosubtypic cross-reactivity of h1n1 pandemic" exact="influenza" post="vaccineSci. Rep.201774483910.1038/srep4483928322289 13.NguyenQ.T.KwakC.LeeW.S.KimJ.JeongJ.SungM.H.YangJ.PooH.Poly-gamma-glutamic acid complexed with alum induces cross-protective"/>
  <result pre="analysis of a phase iii double-blind, randomised controlled trialLancet20073692161217010.1016/S0140-6736(07)60946-517602732 16.KundiM.New" exact="hepatitis" post="b vaccine formulated with an improved adjuvant systemExpert Rev."/>
  <result pre="combination adjuvants on modulating innate and adaptive immune responses to" exact="influenza" post="vaccinationImmune Netw.20171732634210.4110/in.2017.17.5.32629093654 29.SteinmanR.M.Linking innate to adaptive immunity through dendritic"/>
  <result pre="after dendritic-cell vaccinationNat. Med.20051174875610.1038/nm125715951824 35.BlackS.Della CioppaG.MalfrootA.NacciP.NicolayU.PellegriniM.SokalE.VertruyenA.Safety of mf59-adjuvanted versus non-adjuvanted" exact="influenza" post="vaccines in children and adolescents: An integrated analysisVaccine2010287331733610.1016/j.vaccine.2010.08.07520813217 36.StassijnsJ.BollaertsK.BaayM.VerstraetenT.A"/>
  <result pre="much of a good thingPLoS Pathog.201814e100739010.1371/journal.ppat.100739030571771 39.SimonW.L.SalkH.M.OvsyannikovaI.G.KennedyR.B.PolandG.A.Cytokine production associated with" exact="smallpox" post="vaccine responsesImmunotherapy201461097111210.2217/imt.14.7225428648 40.ChristianL.M.PorterK.KarlssonE.Schultz-CherryS.Proinflammatory cytokine responses correspond with subjective side"/>
  <result pre="responsesImmunotherapy201461097111210.2217/imt.14.7225428648 40.ChristianL.M.PorterK.KarlssonE.Schultz-CherryS.Proinflammatory cytokine responses correspond with subjective side effects after" exact="influenza" post="virus vaccinationVaccine2015333360336610.1016/j.vaccine.2015.05.00826027906 41.AmannaI.J.SlifkaM.K.Contributions of humoral and cellular immunity to"/>
  <result pre="experiments. Figure 6 EcML enhances the protective efficacy of the" exact="influenza" post="vaccine antigen. C57BL/6 mice (n = 6 per group)"/>
  <result pre="vaccination, the mice were i.n. challenged with 50 LD50 pH1N1" exact="influenza" post="virus. Body weight changes and survival rates were monitored"/>
  <result pre="after the final administration, and the endpoint titers of the" exact="influenza" post="vaccine antigen-specific Abs are expressed as the means Â±"/>
  <result pre="Splenocytes from the immunized mice were stimulated with UV-inactivated pH1N1" exact="influenza" post="(500 median tissue culture infectious dose (TCID50)/well) for 3"/>
  <result pre="infectious dose (TCID50)/well) for 3 days, and the numbers of" exact="influenza" post="virus-specific IFN-Î³ SFUs were then determined using ELISPOT assay."/>
  <result pre="Splenocytes from the immunized mice were stimulated with UV-inactivated pH1N1" exact="influenza" post="virus (500 TCID50/well) for 5 days. The levels of"/>
 </snippets>
</snippetsTree>
